Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2021.08.18

Discovery biology facility

Sai Life Sciences opens new Discovery Biology facility at its integrated R&D campus in Hyderabad, India

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO-CDMO), today announced the opening of a new biology facility at its integrated R&D campus in Hyderabad, India. The facility marks an important milestone in the journey of positioning itself as a differentiated player in Discovery Biology.

Making the announcement, CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri said, “The new facility marks the culmination of a journey we began two years ago, of creating differentiated value for our discovery clients through an integrated delivery model across Boston and Hyderabad. By bringing the best of talent, technology, complementary services and efficiency we are confident of bringing unique value to our clients and are keen to take on integrated discovery mandates, at scale.”

Continuing with the company’s aggressive growth in its biology services, the new state-of-the-art facility houses expanded in vitro and in vivo biology services, DMPK, toxicology and a vivarium. In this new facility Sai Life Sciences is augmenting both, its capabilities and capacity, to deploy cutting-edge platforms and technologies for accelerating integrated drug discovery programs.

Boston-Hyderabad integrated delivery model

Sai Life Sciences has been steadily growing its biology capabilities to complement its strong foundation in medicinal chemistry, DMPK and toxicology for supporting its customers across the entire drug discovery journey from target ID and validation to IND. In 2019, the company opened its first international R&D facility with a biology lab in Boston, USA. The Boston Biology Lab is designed to offer start-up and biotech companies in the region biology services to address exploratory and custom biology needs.

The company’s integrated delivery model for Biology aims to provide its clients an optimal solution in terms of expertise, speed, and cost. In this model, critical exploratory work involving close hand-in-hand collaboration with clients is done at the Boston lab, following which, established assays are tech transferred to Hyderabad for greater throughput. A seamless and rapid technology transfer across sites is achieved through a unified global organization and matching infrastructure across both sites. Encouraged by the initial success with the Boston-Hyderabad integrated model, the company plans to expand its capacity at both locations in the coming months.

The company’s discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others. With a strong track record of enduring customer relationships averaging 10+ years, Sai Life Sciences has advanced 35+ programs to different clinical phases (IND to Phase-III) with the average turnaround time from Hit/Lead to Candidate being 18 months.

The opening of the new biology block in Hyderabad culminates the company’s journey of unifying its discovery, early & late phase development and clinical supply capabilities in a single 13-acre campus housing over 1000 scientists, delivering integrated value at scale.

Share article

More News

2024.02.08

Sai Life Sciences releases its Sustainability Report 2023

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), released its Sustainability Report 2022-2023. Developed in accordance with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, the fourth edition of the Sustainability report is based on the theme ‘Steadfast on Sustainability,’ and it articulates the company’s commitment to sustainability […]
Read more

2024.02.01

Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has expanded its DMPK capabilities. The expansion comprises the addition of 25,000 sq. ft. of state-of-the-art labs equipped with cutting-edge instrumentation enabling high-end automation. Complementing the expansion has been […]
Read more

2024.01.24

Sai Life Sciences strengthens discovery leadership

Sai Life Sciences, a leading global contract research, development, and manufacturing organization, announces the addition of two seasoned professionals to its leadership team. Dr Atul Tiwari joins as Vice President – Discovery Strategy & Business, while Dr Santosh Kulkarni takes on the role of Vice President – Medicinal Chemistry. Their wealth of experience promises to […]
Read more

2023.12.21

Sai Life Sciences wins Gold in Brandon Hall Group’s Excellence in Technology Awards

Sai Life Sciences won Gold in Brandon Hall Group’s Excellence in Technology Awards in the ‘Best Advance in Content Authoring Technology’ category. Sai Life Sciences was recognized for the use of UL Create Tool, an easy-to-use, cloud-based authoring tool from UL Solutions, for making the learning process seamless and effective for all. The company utilized […]
Read more

2023.08.21

Sai Life Silver Jubilee year

Sai Life Sciences enters its Silver Jubilee year; surpasses vision of 25 commercial molecules by 2025

Sai Life Sciences entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various […]
Read more